These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7958464)

  • 41. Update on HIV vaccines.
    Meldorf M; Corey L
    STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues.
    Rowland SS; Mayner RL; Barker L
    Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Duration of immunity (DOI)--The regulatory issues.
    Gaskell RM; Dawson S; Radford AD
    Vet Microbiol; 2006 Oct; 117(1):80-5. PubMed ID: 16723198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulating recombinant DNA biologics.
    Crouch ML
    Arzneimittelforschung; 1988 Jul; 38(7):947-9. PubMed ID: 3207440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Translational research on vaccines: influenza as an example.
    Belshe RB
    Clin Pharmacol Ther; 2007 Dec; 82(6):745-9. PubMed ID: 17971813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Recombinant viruses of poultry as vector vaccines against fowl plague].
    Fuchs W; Veits J; Mettenleiter TC
    Berl Munch Tierarztl Wochenschr; 2006; 119(3-4):160-6. PubMed ID: 16573206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
    Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF
    Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
    Xing Z; Charters TJ
    Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assuring the safety and efficacy of DNA vaccines.
    Griffiths E
    Ann N Y Acad Sci; 1995 Nov; 772():164-9. PubMed ID: 8546389
    [No Abstract]   [Full Text] [Related]  

  • 51. Current status and future trends in vaccine regulation--USA.
    Falk LA; Ball LK
    Vaccine; 2001 Feb; 19(13-14):1567-72. PubMed ID: 11166876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasmid DNA for human gene therapy and DNA vaccines. Production and quality assurance.
    Schorr J; Moritz P; Seddon T; Schleef M
    Ann N Y Acad Sci; 1995 Nov; 772():271-3. PubMed ID: 8546406
    [No Abstract]   [Full Text] [Related]  

  • 53. 2nd forum in virology. Vaccinia-vectored vaccines--risks and benefits.
    Res Virol; 1989; 140(5):461-91. PubMed ID: 2587850
    [No Abstract]   [Full Text] [Related]  

  • 54. USDA licensing policy for biologicals produced by R-DNA.
    Espeseth DA; Shibley GP; Joseph PL; van Deusen RA; Whetstone CA
    Dev Biol Stand; 1985; 59():167-73. PubMed ID: 4007275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Obtaining marketing authorization for nucleic acid vaccines in the European Union.
    Cichutek K
    Ann N Y Acad Sci; 1995 Nov; 772():178-85. PubMed ID: 8546391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulatory issues in the use of DNA vaccines.
    Minor PD
    Ann N Y Acad Sci; 1995 Nov; 772():170-7. PubMed ID: 8546390
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety issues relating to the use of mammalian cells as hosts.
    Petricciani JC
    Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The history of regulatory system for plasma fractionation products in the United States].
    Fukuzawa M; Tsutani K
    Yakushigaku Zasshi; 2014; 49(2):205-13. PubMed ID: 25799842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of biosafety guidelines. Biosafety Task Force, Parenteral Drug Association.
    J Parenter Sci Technol; 1989; 43(6):252-8. PubMed ID: 2600729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. License requirements for recombinant DNA veterinary biologics in U.S.A.
    La Salle B
    Dev Biol Stand; 1985; 59():181-4. PubMed ID: 4007277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.